Aflibercept-FOLFIRI

DRUG2 trials

Sponsors

Centre Oscar Lambret, Hôpital Franco-Britannique-Fondation Cognacq-Jay

Conditions

Cancer ColorectalMetastasisMetastatic Colorectal Cancer

Phase 2

Aflibercept and Chemotherapy as First Line Treatment for Metastatic Colorectal Cancer Assessable With DCE-US (PULSAR).

TerminatedNCT02173990

Centre Oscar LambretMetastatic Colorectal Cancer

Start: 2014-07-31End: 2019-10-22Updated: 2021-10-20

Phase 3

TWICE-IRI: Optimization of Second-line Therapy With Aflibercept, Irinotecan (Day 1 or Day 1,3), 5-Fluorouracile and Folinic Acid in Patients With Metastatic Colorectal Cancer. A Randomized Phase III Study.

Hôpital Franco-Britannique-Fondation Cognacq-JayCancer Colorectal, Metastasis

Start: 2020-09-02End: 2024-06-30Target: 202Updated: 2023-10-23

Related Papers

Ziv-aflibercept (A) combined to FOLFIRI as first line treatment for metastatic colorectal cancer (mCRC): Interim safety and efficacy results of the phase II PULSAR trial.

Journal of Clinical Oncology2017-02-01